Liek s účinnou látkou palivizumab

TENDER DESCRIPTION

Subject of the contract: Medicine with the active ingredient palivizumab Palivizumab is a recombinant humanized monoclonal antibody produced by DNA technology in mouse myeloma host cells. One 0.5 ml injection vial contains 50 mg of palivizumab The medicine is indicated for the prevention of severe lower respiratory tract disease requiring hospitalization caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease: • children born at the 35th week of gestation or earlier and who are younger than 6 months at the beginning of the RSV season; • children up to 2 years old who have required treatment for bronchopulmonary dysplasia within the past 6 months; • children up to 2 years old with hemodynamically significant congenital heart disease Subject of the contract: Medicine with the active ingredient palivizumab Palivizumab is a recombinant humanized monoclonal antibody produced by DNA technology in mouse myeloma host cells. One 0.5 ml injection vial contains 50 mg of palivizumab The medicine is indicated for the prevention of severe lower respiratory tract disease requiring hospitalization caused by respiratory syncytial virus (RSV) in children at high risk of…

TENDER BRIEF

TENDER DOCUMENTS